2. Search Result
Search Result
Results for "

Non-alcoholic+steatohepatitis

" in MedChemExpress (MCE) Product Catalog:

67

Inhibitors & Agonists

1

Screening Libraries

8

Peptides

3

Inhibitory Antibodies

5

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99930
    Efruxifermin
    2 Publications Verification

    AKR-001; AMG-876

    		 FGFR Metabolic Disease
    Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .
    Efruxifermin
  • HY-116374
    Glycolithocholic acid
    2 Publications Verification

    Lithocholylglycine

    		 Endogenous Metabolite Inflammation/Immunology
    Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .
    Glycolithocholic acid
  • HY-145632
    Pemvidutide

    ALT-801

    		 GLP Receptor GCGR Metabolic Disease
    Pemvidutide (ALT-801) is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide can be used in non-alcoholic steatohepatitis (NASH) and obesity research .
    Pemvidutide
  • HY-147246
    Berberine ursodeoxycholate
    1 Publications Verification

    HTD1801; BUDCA

    		 Biochemical Assay Reagents Metabolic Disease
    Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes .
    Berberine ursodeoxycholate
  • HY-P991049
    Atrosimab

    ATM-001

    		 TNF Receptor Metabolic Disease Inflammation/Immunology
    Atrosimab is an Fv-Fc1K fusion protein with an EC50 value of 0.37 nM against humans. Atrosimab inhibits TNF-induced TNFR1 activation, release of IL-6 and IL-8, and cell death, and alleviates neuroinflammation. Atrosimab is applicable to research related to inflammatory diseases, neurodegenerative diseases, acute and chronic inflammation, experimental arthritis, non-alcoholic steatohepatitis, and experimental autoimmune encephalomyelitis .
    Atrosimab
  • HY-W011121
    2-Oleoylglycerol
    1 Publications Verification

    2-OG

    		 GPR119 NF-κB TGF-beta/Smad GLP Receptor Metabolic Disease
    2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC50 value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) .
    2-Oleoylglycerol
  • HY-115319
    CP-24879 hydrochloride
    2 Publications Verification

    		 Ferroptosis Inflammation/Immunology
    CP-24879 (hydrochloride) is a potent, selective and combined delta5D/delta6D inhibitor. CP-24879 (hydrochloride) can significantly reduce intracellular lipid accumulation and inflammatory injury in hepatocytes. CP-24879 (hydrochloride) exhibits superior antisteatotic and anti-inflammatory actions in fat-1 and ω-3-treated hepatocytes, and can be used for non-alcoholic steatohepatitis research .
    CP-24879 hydrochloride
  • HY-B1245
    Salsalate
    2 Publications Verification

    Salicylsalicylic acid; Disalicylic acid

    		 Reactive Oxygen Species (ROS) Inflammation/Immunology Cancer
    Salsalate is a potent antirheumatic drug with oral activity that reduces irritation during gastric absorption and avoids direct inhibition of cyclooxygenase. Salsalate not only has significant anti-inflammatory effects, but also reduces blood sugar levels, improves insulin resistance, and reduces the expression of cytokines. Salsalate can protect mice from metabolic disorders caused by high-fat diet and effectively improve the symptoms of type 2 diabetes, atherosclerosis and non-alcoholic steatohepatitis [2 ] .
    Salsalate
  • HY-100008
    Peretinoin
    Maximum Cited Publications
    7 Publications Verification

    NIK333

    		 RAR/RXR SphK Autophagy HCV Infection Cancer
    Peretinoin is an oral acyclic retinoid with a vitamin A-like structure that targets retinoid nuclear receptors such as retinoid X receptor (RXR) and retinoic acid receptor (RAR). Peretinoin reduces the mRNA level of sphingosine kinase 1 (SPHK1) in vitro by downregulating a transcription factor, Sp1 . Peretinoin prevents the progression of non-alcoholic steatohepatitis (NASH) and the development of hepatocellular carcinoma (HCC) through activating the autophagy pathway by increased Atg16L1 expression . Peretinoin inhibits HCV RNA amplification and virus release by altering lipid metabolism with a EC50 of 9 μM .
    Peretinoin
  • HY-P99143
    Anti-Mouse NK1.1 Antibody (PK136)

    		Neurokinin Receptor NF-κB STAT Inflammation/Immunology
    Anti-Mouse NK1.1 Antibody (PK136) is an anti-mouse NK1.1 IgG2a monoclonal antibody. Anti-Mouse NK1.1 Antibody (PK136) can deplete natural killer (NK) cells. Anti-Mouse NK1.1 Antibody (PK136) inhibits the JAK-STAT and NF-κB signaling pathways. Anti-Mouse NK1.1 Antibody (PK136) can be used for research on inflammation conditions such as non-alcoholic steatohepatitis (NASH) .
    Anti-Mouse NK1.1 Antibody (PK136)
  • HY-101190
    Volixibat

    SHP626; LUM002

    		 Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    Volixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH) .
    Volixibat
  • HY-143613
    THR-β agonist 2

    		Thyroid Hormone Receptor Metabolic Disease
    THR-β agonist 2 is a potent agonist of THR-β. THR-β agonist 2 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021121210A1, compound 3) .
    THR-β agonist 2
  • HY-P10302A
    GLP-1R/GIPR agonist-1 (soduim)

    		GLP Receptor Metabolic Disease Inflammation/Immunology
    GLP-1R/GIPR agonist-1 sodium is a dual GLP-1/GIP receptor agonist, with an EC50 of 0.57 nM for GLP-1R and an EC50 of 0.75 nM for GIPR. GLP-1R/GIPR agonist-1 sodium reduces food intake, inhibits weight gain, repairs islet damage, improves glucose tolerance, regulates serum lipid and liver enzyme levels, ameliorates hepatic vacuolization, reduces hepatic fat accumulation, delays the progression of hepatic fibrosis, and exhibits long-lasting hypoglycemic activity. GLP-1R/GIPR agonist-1 sodium can be used in research related to type 2 diabetes, obesity, and non-alcoholic steatohepatitis .
    GLP-1R/GIPR agonist-1 (soduim)
  • HY-N1775
    3',4'-Dihydroxyacetophenone

    3,4-DHAP

    		 Tyrosinase Reactive Oxygen Species (ROS) Keap1-Nrf2 PARP Autophagy Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    3',4'-Dihydroxyacetophenone (3,4-DHAP) is a phenolic compound with oral bioavailability, possessing potent antioxidant, anti-inflammatory, anticancer and cardiovascular protective activities. 3',4'-Dihydroxyacetophenone inhibits mushroom Tyrosinase activity with an IC50 of 10 μM, thereby suppressing melanogenesis . 3',4'-Dihydroxyacetophenone inhibits platelet aggregation in platelet-rich plasma. 3',4'-Dihydroxyacetophenone reduces ROS levels in human umbilical vein endothelial cells treated with high glucose, upregulates the expression of Nrf2, HO-1 and PARP-1 in cells, and promotes the nuclear translocation of Nrf2 . 3',4'-Dihydroxyacetophenone induces autophagy and apoptosis. 3',4'-Dihydroxyacetophenone inhibits seed germination/growth in most plants. 3',4'-Dihydroxyacetophenone can be used in the research of cancer, neurodegenerative diseases, non-alcoholic steatohepatitis, diabetes, obesity, skin pigmentation disorders, and cardiovascular and cerebrovascular diseases .
    3',4'-Dihydroxyacetophenone
  • HY-147296
    Omesdafexor

    MET409

    		 FXR Inflammation/Immunology Cancer
    Omesdafexor (MET409) is an orally active FXR agonist with a unique non-bile acid structure. Omesdafexor can be used for the study of non-alcoholic steatohepatitis (NASH) .
    Omesdafexor
  • HY-W044764
    2-Benzylsuccinic acid
    1 Publications Verification

    DL-Benzylsuccinic acid

    		 Carboxypeptidase Neurological Disease Metabolic Disease
    2-Benzylsuccinic acid (DL-Benzylsuccinic acid) is an orally active carboxypeptidase A and Nna1 inhibitor. 2-Benzylsuccinic acid reduces cold hyperalgesia. 2-Benzylsuccinic acid can be used for the researches of neuropathic pain, non-alcoholic steatohepatitis .
    2-Benzylsuccinic acid
  • HY-134988
    EDP-305

    		FXR Phosphatase Cytochrome P450 Inflammation/Immunology
    EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC50 values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .
    EDP-305
  • HY-156259
    PF-07202954

    		Acyltransferase Inflammation/Immunology
    PF-07202954 is an orally active, highly selective DGAT2 inhibitor with an IC50 of 10 nM against human DGAT2 and an IC50 of 17 nM against rat DGAT2. PF-07202954 reduces triglyceride synthesis, decreases hepatic triglyceride content and plasma triglyceride levels, inhibits de novo lipogenesis, and suppresses the hepatic SREBP signaling pathway as well as the expression of SREBP target genes. PF-07202954 is applicable to research related to non-alcoholic steatohepatitis .
    PF-07202954
  • HY-116374A
    Glycolithocholic acid sodium
    2 Publications Verification

    Lithocholylglycine sodium

    		 Endogenous Metabolite Metabolic Disease
    Glycolithocholic acid (Lithocholylglycine) sodium is the sodium salt of Glycolithocholic acid. Glycolithocholic acid is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .
    Glycolithocholic acid sodium
  • HY-153476A
    GIP/GLP-1 dual receptor agonist-1 sodium

    		GLP Receptor GCGR Inflammation/Immunology
    GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
    GIP/GLP-1 dual receptor agonist-1 sodium
  • HY-153476
    GIP/GLP-1 dual receptor agonist-1

    		GCGR GLP Receptor Inflammation/Immunology
    GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
    GIP/GLP-1 dual receptor agonist-1
  • HY-113111
    11,12-DiHETrE

    		Drug Metabolite Inflammation/Immunology
    11,12-DiHETrE is a dihydroxy fatty acid metabolite of Arachidonic Acid (HY-109590). 11,12-DiHETrE is converted to 11,12-DiHETrE under elevated soluble epoxide hydrolase (sEH) activity, a process closely related to inflammation and oxidative stress. 11,12-DiHETrE can serve as a single biomarker to differentiate between NAFL (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis). 11,12-DiHETrE can be used in studies on preterm birth, autism, and pulmonary hypertension .
    11,12-DiHETrE
  • HY-145632A
    Pemvidutide TFA

    ALT-801 TFA

    		 GLP Receptor GCGR Metabolic Disease
    Pemvidutide (ALT-801) TFA is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide TFA can be used in non-alcoholic steatohepatitis (NASH) and obesity research .
    Pemvidutide TFA
  • HY-163649
    A17

    		AMPK Metabolic Disease
    A17 is a bile acid analog with anti-non-alcoholic steatohepatitis (NASH) and anti-inflammatory activities. A17 reduces fatty acid (FA) uptake and promotes FA oxidation though inhibiting fatty acid translocase (Cd36) expression and activating AMPKα. A17 can be used for NASH research .
    A17
  • HY-169792
    HPG1860

    		FXR Aminotransferases (Transaminases) Metabolic Disease Inflammation/Immunology
    HPG1860 is an orally active, highly selective and potent FXR agonist, with an EC50 of 18 nM (FXR-luciferase reporter assay). HPG1860 has EC50 values >30.0 μM for TGR5 and 13 other related nuclear receptors (cAMP biological assay). HPG1860 can be used for the research of non-alcoholic steatohepatitis (NASH) .
    HPG1860
  • HY-W996116
    AZM198

    		Glutathione Peroxidase Cardiovascular Disease Neurological Disease Inflammation/Immunology
    AZM198 is an orally active myeloperoxidase (MPO) inhibitor. AZM198 irreversibly inactivates MPO (IC50=0.015 μM) via covalent binding to the heme prosthetic group, preferentially targets extracellular MPO activity, and reduces neutrophil extracellular trap formation, reactive oxygen species production and degranulation. AZM198 increases the fibrous cap thickness of atherosclerotic plaques, reduces lesion area, ameliorates hepatic steatosis and fibrosis in non-alcoholic steatohepatitis, and alleviates proteinuria and inflammatory infiltration associated with glomerulonephritis. AZM198 also decreases circulating levels of high-sensitivity Cardiac Troponin I and IL-1β, and mitigates endothelial cell injury. Therefore, AZM198 is suitable for research on various MPO-related diseases, including atherosclerotic cardiovascular disease, myocardial infarction, ischemic stroke, non-alcoholic steatohepatitis and crescentic glomerulonephritis .
    AZM198
  • HY-109002
    Apararenone

    MT-3995

    		 Mineralocorticoid Receptor Cardiovascular Disease Metabolic Disease
    Apararenone (MT-3995) is a novel non-steroidal mineralocorticoid receptor antagonists under development for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.
    Apararenone
  • HY-19522C
    Seladelpar (lysine dihydrate)
    1 Publications Verification

    MBX-8025 (lysine dihydrate); RWJ-800025 (lysine dihydrate)

    		 PPAR Interleukin Related Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Seladelpar Lysine dihydrate (MBX-8025 lysine dihydrate) is an orally active, selective PPAR-δ agonist with an EC50 of 2 nM against hPPAR-δ. Seladelpar Lysine dihydrate reduces serum IL-31 and bile acid levels. It alleviates pruritus symptoms. Seladelpar Lysine dihydrate enhances insulin sensitivity, normalizes levels of hyperglycemia, hyperinsulinemia, glucose disposal capacity, serum lipids and hepatic free cholesterol. It reduces steatosis, hepatic inflammation and improves liver fibrosis. Seladelpar Lysine dihydrate reverses the pathological changes of non-alcoholic steatohepatitis (NASH). It is applicable to research related to primary biliary cholangitis and non-alcoholic steatohepatitis (NASH) .
    Seladelpar (lysine dihydrate)
  • HY-116374S
    Glycolithocholic acid-d4

    		Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease Inflammation/Immunology
    Glycolithocholic acid-d4 is the deuterium labeled Glycolithocholic acid. Glycolithocholic acid, an endogenous metabolite, is a glycine-conjugated secondary bile acid and can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .
    Glycolithocholic acid-d4
  • HY-144035
    GLP-1R agonist 4

    		GCGR Metabolic Disease Inflammation/Immunology
    GLP-1R agonist 4 is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 4 can be used for the research of type 2 diabetes mellitus, obesity, non-alcoholic steatohepatitis, insulin resistance and etc .
    GLP-1R agonist 4
  • HY-141439
    TBE 31

    		Keap1-Nrf2 Quinone Reductase Glutathione S-transferase Apoptosis TNF Receptor Inflammation/Immunology Cancer
    TBE 31 is an orally active Keap1/Nrf2 pathway activator and NQO1 inducer with a Dm value of 1.1 nM for NQO1. TBE 31 binds to cysteine residues of Keap1, inhibits ubiquitination and degradation of Nrf2, thereby activating the expression of ARE-dependent genes. TBE 31 induces cytoprotective enzymes including NQO1 and GST isoforms, promotes Nrf2 accumulation, and upregulates Nrf2-regulated genes related to antioxidation and lipid metabolism. TBE 31 inhibits pro-inflammatory responses, formation of AFB1-DNA adducts, endoplasmic reticulum stress, cell apoptosis (apoptosis), hepatic fibrosis, oxidative stress, and the expression of ChREBP. TBE 31 reduces the number of tumors in a mouse model of ultraviolet-induced skin carcinogenesis. TBE 31 enhances nerve growth factor-induced neurite outgrowth. TBE 31 attenuates LPS-induced serum TNF-α levels and immobility time in mice. TBE 31 can be used in research related to liver cancer, skin cancer, inflammation-related depression, and non-alcoholic steatohepatitis .
    TBE 31
  • HY-116374R
    Glycolithocholic acid (Standard)

    Lithocholylglycine (Standard)

    		 Endogenous Metabolite Reference Standards Inflammation/Immunology
    Glycolithocholic acid (Standard) is the analytical standard of Glycolithocholic acid. This product is intended for research and analytical applications. Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .
    Glycolithocholic acid (Standard)
  • HY-150191
    IMA-1

    		Lipoxygenase Acetyl-CoA Carboxylase Metabolic Disease
    IMA-1 is an inhibitor that inhibits the interaction between arachidonic acid 12-lipoxygenase (ALOX12) and acetyl-CoA carboxylase 1 (ACC1). IMA-1 significantly blocks the progression of diet-induced non-alcoholic steatohepatitis (NASH) in male mice and crab-eating monkeys, and does not cause hyperlipidemia. IMA-1 can be used for the study of NASH .
    IMA-1
  • HY-N16066
    Candidusin A

    CHNQD-0803

    		 AMPK Apoptosis NF-κB TNF Receptor Inflammation/Immunology
    Candidusin A (CHNQD-0803) (Compound 4) is a AMPK activator with a KD of 47.28 nM. Candidusin A can be isolated from marine fungus Aspergillus candidus. Candidusin A has cytotoxic activity and induces apoptosis in human prostate cancer cells (22Rv1, PC-3 and LNCaP cells). Candidusin A reduces adipogenesis genes expression and fat deposition, negatively regulates the NF-κB-TNFα inflammatory axis to suppress inflammation, and ameliorates liver injury and fibrosis. Candidusin A can be used for non-alcoholic steatohepatitis (NASH) research .
    Candidusin A
  • HY-P10302
    GLP-1R/GIPR agonist-1

    		GLP Receptor Insulin Receptor Metabolic Disease
    GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
    GLP-1R/GIPR agonist-1
  • HY-153114
    HEC96719

    		FXR Inflammation/Immunology
    HEC96719 is a selective and orally active tricyclic farnesoid X receptor (FXR) agonist with EC50 values of 1.37 and 1.55 nM by time-resolved fluorescence energy transfer (TR-FRET) and luciferase reporter assays, respectively. HEC96719 significantly improves non-alcoholic steatohepatitis (NASH) and liver fibrosis with favorable tissue distribution in liver and intestine. HEC96719 can be used for the research of non-alcoholic steatohepatitis .
    HEC96719
  • HY-P11042
    TE-8105

    		GLP Receptor Metabolic Disease
    TE-8105 is a GLP-1 receptor agonist that has demonstrated prolonged and potent efficacy in models of diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
    TE-8105
  • HY-173565
    ACC-IN-1

    		Acetyl-CoA Carboxylase Inflammation/Immunology
    ACC-IN-1 (Compound B1) is an allosteric inhibitor of acetyl-CoA carboxylase (ACC). ACC-IN-1 targets ACC to regulate lipid metabolism, which can improve liver steatosis, inflammation related to non-alcoholic steatohepatitis (NASH) .
    ACC-IN-1
  • HY-175985
    MPO-IN-9

    		Reactive Oxygen Species (ROS) Inflammation/Immunology
    MPO-IN-9 is a selective inhibitor of myeloperoxidase (MPO), with an IC50 value of 3.9 nM. MPO-IN-9 inhibits MPO-mediated ROS production and protects NO-dependent vascular function by blocking MPO's chlorination and peroxidation cycles. MPO-IN-9 can be used for the study of diseases such as chronic kidney disease (CKD), non-alcoholic steatohepatitis (NASH) .
    MPO-IN-9
  • HY-176770
    GLP-1R agonist 34

    		GLP Receptor Metabolic Disease
    GLP-1R agonist 34 (Compound 1) is an orally active small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist. GLP-1R agonist 34 promotes insulin secretion, inhibits glucagon release, and delays gastric emptying, thereby effectively lowering blood glucose levels. GLP-1R agonist 34 is promising for research of metabolic diseases, including type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
    GLP-1R agonist 34
  • HY-171850
    GLP-1R modulator-1

    		GLP Receptor Metabolic Disease Inflammation/Immunology
    GLP-1R modulator-1 (Compound 384) is an orally active, potent selective glucagon-like peptide-1 receptor (GLP-1R) agonist. GLP-1R modulator-1 activates G-protein coupled signaling, elevates intracellular cAMP levels, promotes insulin secretion, delays gastric emptying and suppresses appetite. GLP-1R modulator-1 is promising for research of type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
    GLP-1R modulator-1
  • HY-137922
    SHS4121705

    		Mitochondrial Metabolism Metabolic Disease
    SHS4121705 is an orally effective mitochondrial uncoupling agent with an IC50 of 4.3 μM in L6 myoblasts. SHS4121705 can be used in the study of non-alcoholic steatohepatitis (NASH) .
    SHS4121705
  • HY-149893
    MGAT2-IN-4

    		Acyltransferase Metabolic Disease
    MGAT2-IN-4 (compound 33) is an inhibitor of monoacylglycerol transferase 2 (MGAT2), with liver metabolic stability. MGAT2-IN-4 can be used for research on obesity, diabetes and non-alcoholic steatohepatitis (NASH) .
    MGAT2-IN-4
  • HY-W044764R
    2-Benzylsuccinic acid (Standard)

    		Reference Standards Carboxypeptidase Neurological Disease Metabolic Disease
    2-Benzylsuccinic acid (DL-Benzylsuccinic acid) is an orally active carboxypeptidase A and Nna1 inhibitor. 2-Benzylsuccinic acid reduces cold hyperalgesia. 2-Benzylsuccinic acid can be used for the researches of neuropathic pain, non-alcoholic steatohepatitis .
    2-Benzylsuccinic acid (Standard)
  • HY-170571
    BE2647

    		Mitochondrial Metabolism Metabolic Disease Inflammation/Immunology
    BE2647 is a selective inhibitor for mitochondrial pyruvate carrier (MPC) with an EC50 of 70 nM. BE2647 exhibits good metabolic stability in mouse liver microsomes. BE2647 can be used in research of metabolic diseases, non-alcoholic fatty liver disease (MASLD), or non-alcoholic steatohepatitis (MASH) .
    BE2647
  • HY-168327
    LH10

    		FXR Inflammation/Immunology
    LH10 is a fexaramine-based agonist for FXR with an EC50 of 0.14 μM. LH10 exhibits liver protection efficacy, ameliorates the alpha naphthylisothiocyanate (ANIT)-induced cholestasis, APAP (HY-66005)-induced acute liver injury and non-alcoholic steatohepatitis (NASH) in mouse models .
    LH10
  • HY-P6177
    SGP8

    		Dipeptidyl Peptidase Inflammation/Immunology
    SGP8 (IAVPGEVA) is an octapeptide produced by hydrolysis of soybean 11S globulin, which has the effects of regulating lipid metabolism, inflammation and fibrosis. SGP8 (IAVPGEVA) exhibits inhibitory activity against DPP4 and inhibits the JNK-c-Jun signaling pathway, and has the ability to inhibit non-alcoholic steatohepatitis (NASH) .
    SGP8
  • HY-143614
    THR-β agonist 3

    		Thyroid Hormone Receptor Metabolic Disease
    THR-β agonist 3 is a potent agonist of THR-β. THR-β agonist 3 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021129827A1, compound 6) .
    THR-β agonist 3
  • HY-W750488
    Glycolithocholic acid-d5

    Lithocholylglycine-d5

    		 Isotope-Labeled Compounds Endogenous Metabolite Inflammation/Immunology
    Glycolithocholic acid-d5 (Lithocholylglycine-d5) is the deuterium labeled Glycolithocholic acid (HY-116374). Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .
    Glycolithocholic acid-d5
  • HY-142917
    THR-β agonist 4

    		Thyroid Hormone Receptor Metabolic Disease
    THR-β agonist 4 is a potent agonist of THR-β. THR-β agonist 4 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021143706A1, compound 72) .
    THR-β agonist 4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: